Department of AIDS Research, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
PLoS One. 2012;7(11):e47119. doi: 10.1371/journal.pone.0047119. Epub 2012 Nov 8.
Mutations associated with HIV drug resistance have been extensively characterized at the HIV-1 polymerase domain, but more studies have verified that mutations outside of the polymerase domain also results in resistance to antiviral drugs. In this study, mutations were identified in 354 patients experiencing antiretroviral therapy (ART) failure and in 97 naïve-therapy patients. Mutations whose impact on antiviral drugs was unknown were verified by phenotypic testing.
Pol sequences of HIV subtype B(') obtained from patients experiencing ART failure and from naïve-therapy patients were analyzed for mutations distinct between two groups. Mutations that occurred at a significantly higher frequency in the ART failure than the naïve-therapy group were submitted to the Stanford HIV Drug Resistance Database (SHDB) to analyze the correlation between HIV mutations and drug resistance. For mutations whose impact on the antiviral drug response is unknown, the site-directed mutagenesis approach was applied to construct plasmids containing the screened mutations. 50% inhibitory concentration (IC(50)) to AZT, EFV and NVP was measured to determine the response of the genetically constructed viruses to antiviral drugs.
7 mutations at 6 positions of the RT region, D123E, V292I, K366R, T369A, T369V, A371V and I375V, occurred more frequently in the ART failure group than the naïve-therapy group. Phenotypic characterization of these HIV mutants revealed that constructed viruses with mutations A371V and T369V exhibited dual resistance to AZT and EFV respectively, whereas the other 5 mutations showed weak resistance. Although the impact of the other six mutations on response to NVP was minimal, mutation T369V could enhance resistance to NVP.
This study demonstrated that mutations at the RT C-terminal in subtype B' could result in resistance to RT inhibitors if the mutations occurred alone, but that some mutations could promote susceptibility to antiviral drugs.
已广泛研究 HIV-1 聚合酶结构域中与 HIV 耐药相关的突变,但更多研究证实,聚合酶结构域外的突变也会导致抗病毒药物耐药。本研究对 354 例接受抗逆转录病毒治疗(ART)失败和 97 例初治患者进行了分析。对那些影响抗病毒药物作用的未知突变进行表型检测验证。
从接受 ART 失败和初治患者中获得的 HIV 亚型 B'的 Pol 序列,分析两组之间的突变。ART 失败组中明显高于初治组的突变,提交给斯坦福 HIV 耐药数据库(SHDB),分析 HIV 突变与耐药性之间的相关性。对于那些影响抗病毒药物反应的未知突变,应用定点突变方法构建含有筛选突变的质粒。测量 50%抑制浓度(IC(50))来评估 AZT、EFV 和 NVP 对基因构建病毒的抗病毒药物反应。
RT 区 6 个位置的 7 个突变(D123E、V292I、K366R、T369A、T369V、A371V 和 I375V)在 ART 失败组中比初治组更常见。这些 HIV 突变体的表型特征表明,携带突变 A371V 和 T369V 的构建病毒对 AZT 和 EFV 分别表现出双重耐药性,而其他 5 个突变则表现出弱耐药性。虽然其他 6 个突变对 NVP 反应的影响很小,但 T369V 突变可以增强对 NVP 的耐药性。
本研究表明,B'亚型 RT 结构域 C 末端的突变如果单独发生,可能导致 RT 抑制剂耐药,但某些突变可促进对抗病毒药物的敏感性。